Innovative Medicines Canada (IMC) has said that the PMPRB’s Revised Draft Guidelines have too much ambiguity and could reduce the availability of new medicines in Canada.
It is estimated that in 2022, 24,600 Canadians will be diagnosed with prostate cancer, and 4,600 Canadians will die from it. This represents 10% of male cancer deaths in the country.